deltaDOT Ltd receives £3 million ($6.05 million) from investors

London, UK, 1 October 2007…. deltaDOT Ltd, a developer of innovative molecular imaging technologies and products for bioscience research and biological production, today announced that it has received £3 million in a fourth and final tranche of funding from the investors in its last private equity financing round, following the continuing success of the business. This brings the total raised in the round to £6 million ($12.1 million).

The funding round, which was announced in March 2006, comprised a syndicate of investors including FF&P Private Equity, Imperial Innovations, NPI Ventures, Sitka Health Fund VCT and London Technology Fund. FF&P Private Equity, the private equity division of Fleming Family & Partners (FF&P), acted as lead investor.

Anthony Baxter, CEO of deltaDOT said: “This funding highlights the success of deltaDOT and our recent corporate deals. We are already achieving our sales targets for Peregrine, our High Throughput Capillary Electrophoresis systems, and the funds raised will enable us to increase the production capacity for our Peregrine system. We will also develop our international sales and marketing function, particularly in the USA, which has already been expanded with a number of recent appointments to the board of directors and management team.” The funding will also be used to continue to develop a number of other capillary and microfluidic products for molecular imaging, in particular the Osprey protein unfolding instrument which is set to improve on current thermal analysis of proteins currently employed by Differential Scanning Calorimetry (DSC) and Isothermal Titration Calorimetry (ITC).

deltaDOT’s products make use of a novel biomolecule detection technique called Label Free Intrinsic Imaging (LFIITM). This applies innovations in high-energy physics research to biochemical analysis. Unlike conventional techniques, the technology does not require target molecules to be labelled and enables superior data quantification, while reducing throughput times and operating costs.

deltaDOT recently announced that the company is playing a key role in a US Defence Advanced Research Projects Agency (DARPA) funded project to develop technology and processes that will reduce the time it takes to manufacture vaccines and protein therapeutics, to enhance the response to a wide range of biological threats. deltaDOT’s Peregrine High Performance Capillary Electrophoresis and Osprey protein stability technology platforms are being used to analyse product quality in a cost-effective manner throughout product development, from the R&D to the quality control stages. The consortium of four companies, which is led by Xcellerex Inc (Marlborough, MA), received a total of US$7.9 million from the Agency.

- ENDS -

Media Contact for deltaDOT:
Lorna Cuddon,  Gemma Price, Katie Odgaard
Tel: +44 (0)20 7268 3240
Email: deltadot@northbankcommunications.com

About deltaDOT Ltd

deltaDOT (www.deltadot.com) is a biotechnology company that is developing and commercialising highly innovative enabling technologies and products in the bioscience arena. The company was founded in 2000 and is a spin-out from Imperial College of Science, Technology and Medicine in London, UK. It is focused on the harnessing of cutting-edge particle physics technology and its application to the needs of biomolecular separation, including proteins, DNA and RNA analysis. The company has a strong proprietary position and extensive expertise in instrumentation, microfluidics, automation, computing and analysis which will contribute to improvements in knowledge, profitability and process time throughout drug discovery and general life sciences research.

About Peregrine
deltaDOT’s primary product is Peregrine, a High Performance Capillary Electrophoresis instrument for the separation of proteins, peptides, nucleic acids, small molecules and pathogens. Launched in May 2006, Peregrine has been employed by customers in chemistry analysis, proteomics, biopharmaceutical QA/QC and fermentation laboratories in pharma, biotech and diagnostic businesses.

About Label Free Intrinsic Imaging TM (LFIITM)
deltaDOT’s core technology, Label Free Intrinsic Imaging (LFIITM), coupled with proprietary powerful analyses, forms the basis of its product offering. LFIITM allows the direct monitoring of unlabelled biomolecules in real time, resulting in much faster, more accurate results at a fraction of the cost of conventional approaches. Other products being developed are Merlin®, a high throughput protein folding device, and systems capable of rapid, unbiased analysis of genomic, proteomic and chemical content of unknown substances and threats.